Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Avidity Biosciences, Inc.
- Study ID
- NCT07008469
- Phase
- PHASE3
- Status
- Enrolling By Invitation
Conditions
- DM1
- Myotonia
- Myotonic Disorders
- Myotonic Dystrophy
- Myotonic Dystrophy 1
- Myotonic Dystrophy Type 1
- Steinert Disease
- Steinert Myotonic Dystrophy
Eligibility Criteria
- Sex
- ALL
- Age
- 16 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Del-desiran (AOC 1001) — DRUGDel-desiran will be administered by intravenous (IV) infusion.
Study Details
A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
Key Dates
- Start date
- Jul 25, 2025
- Status verified
- Apr 2026
- Primary completion
- Aug 31, 2030
- Completion
- Oct 31, 2030
Study Design
- Enrollment
- 230 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Del-desiranDel-desiran (AOC 1001) will be administered seven times per year for up to 4 years.
Primary Outcome Measure
TEAEs [ Time Frame: From enrollment to the end of treatment at 4 years ]
Locations (17)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California, Los Angeles (UCLA) | Los Angeles | California | 90095 | - |
| Stanford University | Stanford | California | 94305 | - |
| University of Colorado | Denver | Colorado | 80045 | - |
| University of Florida | Gainesville | Florida | 32608 | - |
| University Research Center of South Florida | Tampa | Florida | 33612 | - |
| Indiana University (IU) | Indianapolis | Indiana | 46202 | - |
| Kansas University Medical Center | Kansas City | Kansas | 66205 | - |
| Kennedy Krieger Institute | Baltimore | Maryland | 21205 | - |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | - |
| University of Rochester Medical Center | Rochester | New York | 14642 | - |
| Duke University Medical Center | Durham | North Carolina | 27708 | - |
| Wake Forest | Winston-Salem | North Carolina | 27157 | - |
| Ohio State University | Columbus | Ohio | 43221 | - |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | - |
| Houston Methodist Neurological Institute | Houston | Texas | 77030 | - |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | - |
| University of Washington | Seattle | Washington | 98104 | - |
Find similar trials in Los Angeles, CA
Related Studies
- Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy RegistryRecruiting · University of Rochester · Rochester, New York
- Myotonic Dystrophy Family RegistryRecruiting · Myotonic Dystrophy Foundation · Oakland, California
- Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)Recruiting · Virginia Commonwealth University · La Jolla, California
- Biomarker Development for Muscular DystrophiesRecruiting · Massachusetts General Hospital · Boston, Massachusetts